EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy

Qiong Hu, Feng Li, Kai Yang

PeerJ · 2024

DOI: 10.7717/peerj.17391 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PeerJ, 2024. Verfasst von Qiong Hu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Cetuximab, Oropharyngeal Neoplasms, Cisplatin, Chemoradiotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of cetuximab instead of cisplatin in combination with downstaging radiotherapy for papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma (HPV + OPSCC).

Design

Meta-analysis and systematic evaluation. Data sources The PubMed, Embase, Web of Science, and Cochrane library databases were searched up to June 8, 2023, as well as Clinicaltrials.gov Clinical Trials Registry, China Knowledge Network, Wanfang Data Knowledge Service Platform, and Wiprojournal.com. Eligibility criteria for selecting studies Randomized controlled trials reporting results of standard regimens of cetuximab + radiotherapy vs cisplatin + radiotherapy in treating HPV + OPSCC were included. The primary outcomes of interest were overall survival (OS), progression-free survival (PFS), local regional failure rate (LRF), distant metastasis rate (DM), and adverse events (AE). Data extraction and synthesis Two reviewers independently extracted data and assessed the risk of bias of the included studies. The HR and its 95% CI were used as the effect analysis statistic for survival analysis, while the OR and its 95% CI were used as the effect analysis statistic for dichotomous variables. These statistics were extracted by the reviewers and aggregated using a fixed-effects model to synthesise the data.

Results

A total of 874 relevant papers were obtained from the initial search, and five papers that met the inclusion criteria were included; a total of 1,617 patients with HPV + OPSCC were enrolled in these studies. Meta-analysis showed that OS and PFS were significantly shorter in the cetuximab + radiotherapy group of patients with HPV + OPSCC compared with those in the conventional cisplatin + radiotherapy group (HR = 2.10, 95% CI [1.39–3.15], P = 0.0004; HR = 1.79, 95% CI [1.40–2.29], P < 0.0001); LRF and DM were significantly increased (HR = 2.22, 95% CI [1.58–3.11], P < 0.0001; HR = 1.66, 95% CI [1.07–2.58], P = 0.02), but there was no significant difference in overall grade 3 to 4, acute and late AE overall (OR = 0.86, 95% CI [0.65–1.13], P = 0.28).

Conclusions

Cisplatin + radiotherapy remains the standard treatment for HPV + OPSCC. According to the 7th edition AJCC/UICC criteria, low-risk HPV + OPSCC patients with a smoking history of ≤ 10 packs/year and non-pharyngeal tumors not involved in lymphatic metastasis had similar survival outcomes with cetuximab/cisplatin + radiotherapy. However, further clinical trials are necessary to determine whether cetuximab + radiotherapy can replace cisplatin + radiotherapy for degraded treatment in individuals who meet the aforementioned characteristics, particularly those with platinum drug allergies. Prospero registration number CRD42023445619.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CetuximabOropharyngeal NeoplasmsCisplatinChemoradiotherapyPapillomavirus InfectionsHumansPrognosisSquamous Cell Carcinoma of Head and NeckNeoplasm StagingPapillomaviridaeAntineoplastic Agents, ImmunologicalProgression-Free SurvivalHuman Papillomavirus Viruses

Stichwörter der Autor:innen

CetuximabHuman papillomavirusMeta-analysisOropharyngeal squamous cell carcinomaRadiotherapyStep-down therapy

Substanzen

CetuximabCisplatinAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Zitieren

APA

Hu, Q., Li, F., & Yang, K. (2024). Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy. PeerJ. https://doi.org/10.7717/peerj.17391

Vancouver

Hu Q, Li F, Yang K. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy. PeerJ. 2024. doi:10.7717/peerj.17391

BibTeX
@article{Hu2024,
  author = {Hu, Qiong and Li, Feng and Yang, Kai},
  title = {Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy},
  journal = {PeerJ},
  year = {2024},
  doi = {10.7717/peerj.17391}
}
Kostenlos starten →